Literature DB >> 23689641

Novel POMGnT1 mutations cause muscle-eye-brain disease in Chinese patients.

Hui Jiao1, Hiroshi Manya, Shuo Wang, Yanzhi Zhang, Xiaoqing Li, Jiangxi Xiao, Yanling Yang, Kazuhiro Kobayashi, Tatsushi Toda, Tamao Endo, Xiru Wu, Hui Xiong.   

Abstract

Muscle-eye-brain (MEB) disease is a congenital muscular dystrophy (CMD) phenotype characterized by hypotonia at birth, brain structural abnormalities and ocular malformations. To date, few MEB cases have been reported in China where clinical recognition and genetic confirmatory testing on a research basis are recent developments. Here, we report the clinical and molecular genetics of three MEB disease patients. The patients had different degrees of muscle, eye and brain symptoms, ranging from congenital hypotonia, early-onset severe myopia and mental retardation to mild weakness, independent walking and language problems. This confirmed the expanding phenotypic spectrum of MEB disease with varying degrees of hypotonia, myopia and cognitive impairment. Brain magnetic resonance imaging showed cerebellar cysts, hypoplasia and characteristic brainstem flattening and kinking. Four candidate genes (POMGnT1, FKRP, FKTN and POMT2) were screened, and six POMGnT1 mutations (four novel) were identified, including five missense and one splice site mutation. Pathogenicity of the two novel variants in one patient was confirmed by POMGnT1 enzyme activity assay, protein expression and subcellular localization of mutant POMGnT1 in HeLa cells. Transfected cells harboring this patient's L440R mutant POMGnT1 showed POMGnT1 mislocalization to both the Golgi apparatus and endoplasmic reticulum. We have provided clinical, histological, enzymatic and genetic evidence of POMGnT1 involvement in three unrelated MEB disease patients in China. The identification of novel POMGnT1 mutations and an expanded phenotypic spectrum contributes to an improved understanding of POMGnT1 structure-function relationships, CMD pathophysiology and genotype-phenotype correlations, while underscoring the need to consider POMGnT1 in Chinese MEB disease patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23689641     DOI: 10.1007/s00438-013-0749-5

Source DB:  PubMed          Journal:  Mol Genet Genomics        ISSN: 1617-4623            Impact factor:   3.291


  24 in total

1.  POMGnT1 mutation and phenotypic spectrum in muscle-eye-brain disease.

Authors:  C Diesen; A Saarinen; H Pihko; C Rosenlew; B Cormand; W B Dobyns; J Dieguez; L Valanne; T Joensuu; A-E Lehesjoki
Journal:  J Med Genet       Date:  2004-10       Impact factor: 6.318

2.  Prenatal diagnosis and genetic counseling of a Chinese Alport syndrome kindred.

Authors:  Hongwen Zhang; Jie Ding; Fang Wang; Huixia Yang
Journal:  Genet Test       Date:  2008-03

3.  [Clinical and mutation analysis of a Chinese family with muscle eye brain disease].

Authors:  Hui Jiao; Hui Xiong; Yan-zhi Zhang; Shuo Wang; Yan-ling Yang; Xi-ru Wu
Journal:  Zhonghua Yi Xue Yi Chuan Xue Za Zhi       Date:  2011-10

Review 4.  Muscular dystrophies due to glycosylation defects: diagnosis and therapeutic strategies.

Authors:  Francesco Muntoni; Silvia Torelli; Dominic J Wells; Susan C Brown
Journal:  Curr Opin Neurol       Date:  2011-10       Impact factor: 5.710

5.  Molecular interaction between fukutin and POMGnT1 in the glycosylation pathway of alpha-dystroglycan.

Authors:  Hui Xiong; Kazuhiro Kobayashi; Masaji Tachikawa; Hiroshi Manya; Satoshi Takeda; Tomohiro Chiyonobu; Nobuhiro Fujikake; Fan Wang; Akemi Nishimoto; Glenn E Morris; Yoshitaka Nagai; Motoi Kanagawa; Tamao Endo; Tatsushi Toda
Journal:  Biochem Biophys Res Commun       Date:  2006-10-02       Impact factor: 3.575

6.  Worldwide distribution and broader clinical spectrum of muscle-eye-brain disease.

Authors:  Kiyomi Taniguchi; Kazuhiro Kobayashi; Kayoko Saito; Hideo Yamanouchi; Akira Ohnuma; Yukiko K Hayashi; Hiroshi Manya; Dong Kyu Jin; Munhyang Lee; Enrico Parano; Raffaele Falsaperla; Piero Pavone; Rudy Van Coster; Beril Talim; Alice Steinbrecher; Volker Straub; Ichizo Nishino; Haluk Topaloglu; Thomas Voit; Tamao Endo; Tatsushi Toda
Journal:  Hum Mol Genet       Date:  2003-03-01       Impact factor: 6.150

7.  Loss-of-function of an N-acetylglucosaminyltransferase, POMGnT1, in muscle-eye-brain disease.

Authors:  Hiroshi Manya; Keiwa Sakai; Kazuhiro Kobayashi; Kiyomi Taniguchi; Masao Kawakita; Tatsushi Toda; Tamao Endo
Journal:  Biochem Biophys Res Commun       Date:  2003-06-20       Impact factor: 3.575

Review 8.  Abnormal glycosylation of dystroglycan in human genetic disease.

Authors:  Jane E Hewitt
Journal:  Biochim Biophys Acta       Date:  2009-06-17

9.  Novel POMGnT1 mutations define broader phenotypic spectrum of muscle-eye-brain disease.

Authors:  Ute Hehr; Goekhan Uyanik; Claudia Gross; Maggie C Walter; Axel Bohring; Monika Cohen; Barbara Oehl-Jaschkowitz; Lynne M Bird; Ghiat M Shamdeen; Ulrich Bogdahn; Gerhard Schuierer; Haluk Topaloglu; Ludwig Aigner; Hanns Lochmüller; Jürgen Winkler
Journal:  Neurogenetics       Date:  2007-09-29       Impact factor: 2.660

10.  Protein O-mannosyltransferase activities in lymphoblasts from patients with alpha-dystroglycanopathies.

Authors:  Hiroshi Manya; Céline Bouchet; Akiko Yanagisawa; Sandrine Vuillaumier-Barrot; Susana Quijano-Roy; Yasushi Suzuki; Svetlana Maugenre; Pascale Richard; Toshiyuki Inazu; Luciano Merlini; Norma B Romero; France Leturcq; Isabelle Bezier; Haluk Topaloglu; Brigitte Estournet; Nathalie Seta; Tamao Endo; Pascale Guicheney
Journal:  Neuromuscul Disord       Date:  2007-09-14       Impact factor: 4.296

View more
  2 in total

Review 1.  A Journey with LGMD: From Protein Abnormalities to Patient Impact.

Authors:  Dimitra G Georganopoulou; Vasilis G Moisiadis; Firhan A Malik; Ali Mohajer; Tanya M Dashevsky; Shirley T Wuu; Chih-Kao Hu
Journal:  Protein J       Date:  2021-06-10       Impact factor: 2.371

2.  Novel copy number variation of POMGNT1 associated with muscle-eye-brain disease detected by next-generation sequencing.

Authors:  Xiaona Fu; Haipo Yang; Hui Jiao; Shuo Wang; Aijie Liu; Xiaoqing Li; Jiangxi Xiao; Yanling Yang; Xiru Wu; Hui Xiong
Journal:  Sci Rep       Date:  2017-08-01       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.